The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease - Takeaways - MDSpire

The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease

  • By

  • Yingte Wang

  • Hong Li

  • Jing Zhou

  • Saiyao Zhao

  • Airong Yang

  • Zhiming Li

  • May 8, 2026

  • 0 min

Share

  • 1

    Multimodal neuroimaging is essential for diagnosing and assessing monoclonal antibody treatments for Alzheimer's disease.

  • 2

    Structural MRI identifies cerebral atrophy and amyloid-related imaging abnormalities, crucial for monitoring treatment effects.

  • 3

    PET imaging quantifies Aβ plaque reduction, serving as an objective biomarker for evaluating treatment engagement.

  • 4

    AI technologies enhance the analysis of imaging data, improving clinical decision-making in Alzheimer's treatment.

  • 5

    Challenges remain in imaging sensitivity, treatment response variability, and the need for long-term safety monitoring.

Original Source(s)

The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease

  • by Yingte Wang, Hong Li, Jing Zhou, Saiyao Zhao, Airong Yang, Zhiming Li

  • May 8, 2026

Related Content

Electroacupuncture for treating the cognitive symptoms of Alzheimer’s disease: a randomized controlled trial

Observing and treating pain in people living with dementia in long-term care facilities

Neurological manifestations in people with HIV in HAART era: a cross-sectional multicenter study